IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.
The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.
The US agency says we've got too much data that cannot be reproduced.
A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.
The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.
Big Data is coming and with it the danger of pharmaceutical marketers relying on it too heavily
The tool lets researchers tap into health data from work, meaning the year-long waits for data are over.
Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.
The Kimberly-Clark-backed cold and flu predictor mixes Big Data, and big branding, with an individualized focus.
The state's first patient portal has officially entered development, and the e-health firm leading the effort said that a former WebMD executive joined its board.
Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.
The head of the European Medicines Agency has said it's a matter of how, not if, the body will mandate publication of clinical trials data—and that has pharmas on both sides of the Atlantic sweating the potential implications for global competitiveness.
Seattle-based Appature has signed up several healthcare marketing agencies and business service firms to use its cloud-based relationship marketing platform.
Pharma companies are starting down the Big Data path but are trying to identify the business questions best suited to new analytic techniques.
IMS has added claims data to its real-world evidence (RWE) platform, but can it satisfy industry's demand for RWE as well as a payer can?
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.